Search Result

Results for "

corticotropin-releasing factor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	CRFR (48) Adenylate Cyclase (2) Adrenergic Receptor (1) Bacterial (3) CFTR (7) Drug Derivative (1) Endogenous Metabolite (2) Endothelin-Converting Enzyme (ECE) (1) ERK (3) GABA Receptor (1) Isotope-Labeled Compounds (3) mRNA (1) NF-κB (3) Parasite (3) PTHR (1) Reference Standards (4) Sigma Receptor (1) Vasopressin Receptor (1)
By Research Areas:	Cancer (1) Cardiovascular Disease (6) Endocrinology (19) Inflammation/Immunology (4) Metabolic Disease (11) Neurological Disease (42)
Click Chemistry:	Alkynes (3)
Oligonucleotides:	Transcription Factors (1) mRNA (1)

Inhibitors & Agonists

Peptides

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Click Chemistry

Oligonucleotides

Targets Recommended: CRFR

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B1811

Vasopressin Maximum Cited Publications 6 Publications Verification Arginine vasopressin; Antidiuretic hormone	Endogenous Metabolite	Neurological Disease
Vasopressin is a cyclic nonapeptide that is synthesized centrally in the hypothalamus. Vasopressin participates in the hypothalamic-pituitary-adrenal axis, and regulates pituitary corticotropin secretion by potentiating the stimulatory effects of corticotropin releasing factor. Vasopressin also can act as a neurotransmitter, exerting its action by binding to specific G protein-coupled receptors .

HY-P0086

Corticotropin-releasing factor (human) 3 Publications Verification Human CRF; Human corticotropin-releasing factor	CRFR	Neurological Disease
Corticotropin-releasing factor human (Human CRF) stimulates the synthesis and secretion of adrenocorticotropin in the anterior pituitary.

HY-106203

Crinecerfont SSR-125543	CFTR	Metabolic Disease
Crinecerfont (SSR-125543) is an orally effective corticotropin-releasing factor receptor type-1 (CRF1 receptor) antagonist. Crinecerfont blocks CRF1 receptor signaling to reduce adrenocorticotropic hormone secretion. Crinecerfont improves hypothalamic-pituitary-adrenal axis negative feedback sensitivity in chronically stressed mice. Crinecerfont can be used for the research of chronic stress conditions and classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency . Crinecerfont is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-124475

Antalarmin Maximum Cited Publications 6 Publications Verification	CRFR	Neurological Disease
Antalarmin is a selective nonpeptide corticotropin-releasing factor receptor 1 (CRHR1) antagonist with a K_i of 2.7 nM. Antalarmin can pass through the blood–brain barrier .

HY-P2847

Urocortin II, mouse	CRFR	Metabolic Disease Endocrinology
Urocortin II, mouse is a potent and selective endogenous peptide agonist of *type-2 corticotropin-releasing* factor (CRF2) receptor with K_i** values of 0.66 nM and ﹥100 nM for CRFR2 and CRFR1, respectively. Urocortin II, mouse activates CRF2 receptors in a cAMP/PKA- and Ca ²⁺/CaMKII-dependent manner.Urocortin II, mouse is expressed in discrete areas of the central nervous system, and activates central neurons involved in the processing of visceral sensory information, and in modulating autonomic outflow .

HY-P1752

Urocortin II, human	CRFR Bacterial Parasite NF-κB ERK	Metabolic Disease
Urocortin II, human is a selective endogenous peptide agonist of *type-2 corticotropin-releasing* factor (CRF2) receptor. Urocortin II, human has an effect of promoting satiet and neuroprotective effect. Urocortin II, human also has bactericidal, antiparasitic and pro-inflammation activity. Urocortin II, human can activate NF-κB pathway and ERK1/2 MAP** kinase. Urocortin II, human can reduce pulmonary arterial hypertension and shows cardiac protection effect. Urocortin II, human can be used for the researches of infection, inflammation, metabolic, neurological and cardiovascular disease .

HY-P1852

TIP 39, Tuberoinfundibular Neuropeptide 1 Publications Verification	Adenylate Cyclase PTHR	Neurological Disease
TIP 39, Tuberoinfundibular Neuropeptide is an endogenous PTH2 receptor agonist and antihypertensive agent. TIP 39, Tuberoinfundibular Neuropeptide selectively activates the PTH2 receptor with no activity on the PTH1 receptor, stimulates cAMP production, activates adenylate cyclase, and elevates intracellular calcium levels via mobilization from intracellular stores. TIP 39, Tuberoinfundibular Neuropeptide is highly conserved in humans, mice, and rats. TIP 39, Tuberoinfundibular Neuropeptide is applicable to research related to nociception and inflammation-induced pain .

HY-P0257

Astressin 3 Publications Verification	CRFR	Neurological Disease
Astressin is a potent corticotropin releasing factor (CRF) antagonist.

HY-135542

NBI-27914 2 Publications Verification	CRFR	Others
NBI-27914 is a highly selective, high-affinity non-peptide competitive antagonist of human corticotropin-releasing factor receptor 1 (CRFR1). NBI-27914 primarily binds to the His199 and Met276 sites in the transmembrane domain of the receptor .

HY-12127

Pexacerfont BMS-562086	CRFR	Neurological Disease Endocrinology
Pexacerfont is a selective corticotropin-releasing factor (CRF₁) receptor antagonist with IC₅₀ of 6.1±0.6 nM for human CRF₁ receptor.

HY-14875

Verucerfont GSK561679	CRFR	Neurological Disease Endocrinology
Verucerfont is a corticotropin-releasing factor receptor 1 (CRF1) antagonist with IC₅₀s of ~6.1, >1000 and >1000?nM for CRF1, CRF2, and CRF-BP, respectively.

HY-12129

CP 154526 hydrochloride	CFTR	Neurological Disease
CP 154526 hydrochloride is a potent, brain-penetrant and selective corticotropin-releasing factor receptor 1 (CRF1) antagonist with a K_i of 2.7 nM. CP 154526 hydrochloride shows selective for CRF1 over CRF2 (K_i = >10 μM). CP 154526 hydrochloride has anxiolytic activities .

HY-106203A

Crinecerfont hydrochloride SSR-125543 hydrochloride	CFTR	Metabolic Disease
Crinecerfont (SSR-125543) hydrochloride is an orally effective corticotropin-releasing factor receptor type-1 (CRF1 receptor) antagonist. Crinecerfont hydrochloride blocks CRF1 receptor signaling to reduce adrenocorticotropic hormone secretion. Crinecerfont hydrochloride improves hypothalamic-pituitary-adrenal axis negative feedback sensitivity in chronically stressed mice. Crinecerfont hydrochloride can be used for the research of chronic stress conditions and classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency . Crinecerfont hydrochloride is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-14130

CP 376395	CRFR	Neurological Disease Endocrinology
CP 376395 is a potent, selective, and brain-penetrable Corticotropin releasing factor 1 (CRF1) receptor antagonist .

HY-P2287

Cortagine 3 Publications Verification	CRFR	Neurological Disease
Cortagine is a specific corticotropin-releasing factor receptor subtype 1 (CRF1) agonist with an EC₅₀ of 2.6 nM for rCRF1. Cortagine is an anxiolytic and antidepressive agent in the mouse model .

HY-P1858A

Urocortin III, mouse TFA	CRFR	Cardiovascular Disease Neurological Disease Endocrinology
Urocortin III, mouse TFA is a corticotropin-releasing factor (CRF)-related peptide. Urocortin III preferentially binds and activates CRF-R2 . Urocortin III (Ucn3) is a known component of the behavioral stress response system. Urocortin III and CRF-R2 in the medial amygdala regulate complex social dynamics .

HY-113603

Tildacerfont SPR001; LY2371712	CRFR	Metabolic Disease
Tildacerfont (SPR001; LY2371712) is an orally active, blood-brain barrier-penetrant selective corticotropin-releasing factor type 1 (CRF1) receptor antagonist. Tildacerfont selectively blocks CRF1 receptors, thereby inhibiting the release of pituitary adrenocorticotropic hormone (ACTH). Tildacerfont can be used in research related to congenital adrenal hyperplasia .

HY-P1858

Urocortin III, mouse	CRFR	Cardiovascular Disease Neurological Disease Endocrinology
Urocortin III, mouse is a corticotropin-releasing factor (CRF)-related peptide. Urocortin III preferentially binds and activates CRF-R2 . Urocortin III (Ucn3) is a known component of the behavioral stress response system. Urocortin III and CRF-R2 in the medial amygdala regulate complex social dynamics .

HY-108295

Pivagabine CXB-722	GABA Receptor	Neurological Disease
Pivagabine (CXB 722) is a hydrophobic 4-aminobutyric acid derivative with neuromodulatory activity. Pivagabine penetrates the blood-brain barrier in rats. Pivagabine antagonizes the effects of foot shock on both GABAA receptor function and corticotropin-releasing factor (CRF) concentrations in rat brain .

HY-14367

Emicerfont GW876008	CRFR	Neurological Disease Endocrinology
Emicerfont is a corticotropin-releasing factor type 1 (CRF₁) receptor antagonist with an IC₅₀ of 66 nM.

HY-P1298A

Sauvagine TFA	CRFR	Cardiovascular Disease Neurological Disease
Sauvagine TFA is a corticotropin-releasing factor receptor (CRFR) agonist. Sauvagine TFA activates HM-CRF receptors to stimulate intracellular cAMP accumulation, activates PC-CRF receptors to trigger associated signaling pathways, and stimulates the hypothalamic-pituitary-adrenal axis. Sauvagine TFA can be used for research on central nervous system and blood diseases .

HY-P3019

Urocortin III (human)	CRFR	Cardiovascular Disease Neurological Disease Endocrinology
Urocortin III (human) is a corticotropin-releasing factor (CRF)-related peptide. Urocortin III (human) preferentially binds and activates CRF-R2 and has a discrete central nervous system and peripheral distribution. Urocortin III (human) potently binds to type 2 CRF receptors, specifically mCRF_2β (K_i = 13.5 nM) and rCRF_2α (K_i = 21.7 nM), while demonstrating negligible affinity for hCRF1 (K_i >100 nM). Urocortin III (human) mediates somatostatin-dependent negative feedback control of Insulin (human) (HY-P0035) secretion ^[1][2].

HY-B1811AS1

Vasopressin-d5 TFA Arginine vasopressin-d5 TFA; Antidiuretic hormone-d5 TFA	Isotope-Labeled Compounds	Neurological Disease
Vasopressin-d5 TFA is the TFA salt form of Vasopressin-d5 (HY-B1811S1). Vasopressin-d5 TFA is an isotope-labeled compound of Vasopressin (HY-B1811). Vasopressin is a cyclic nonapeptide that is synthesized centrally in the hypothalamus. Vasopressin participates in the hypothalamic-pituitary-adrenal axis and regulates pituitary corticotropin secretion by potentiating the stimulatory effects of the corticotropin-releasing factor. Vasopressin also can act as a neurotransmitter, exerting its action by binding to specific G protein-coupled receptors .

HY-P1752B

Urocortin II, human acetate	CRFR Bacterial Parasite NF-κB ERK	Metabolic Disease
Urocortin II, human acetate is a selective endogenous peptide agonist of *type-2 corticotropin-releasing* factor (CRF2) receptor. Urocortin II, human acetate has an effect of promoting satiet and neuroprotective effect. Urocortin II, human acetate also has bactericidal, antiparasitic and pro-inflammation activity. Urocortin II, human acetate can activate NF-κB pathway and ERK1/2 MAP** kinase. Urocortin II, human acetate can reduce pulmonary arterial hypertension and shows cardiac protection effect. Urocortin II, human acetate can be used for the researches of infection, inflammation, metabolic, neurological and cardiovascular disease .

HY-P3687

*[Tyr0] Corticotropin Releasing* Factor, ovine**	CRFR	Endocrinology
[Tyr0] Corticotropin Releasing Factor, ovine is a corticotropin releasing factor/hormone isolated from ovine. Corticotropin releasing factor (CRF) is a hypothalamic hormone, stimulates the release of adrenocorticotropic hormone (ACTH) and of β-endorphin .

HY-P1298

Sauvagine	CRFR	Cardiovascular Disease Neurological Disease
Sauvagine is a corticotropin-releasing factor receptor (CRFR) agonist. Sauvagine activates HM-CRF receptors to stimulate intracellular cAMP accumulation, activates PC-CRF receptors to trigger associated signaling pathways, and stimulates the hypothalamic-pituitary-adrenal axis. Sauvagine can be used for research on central nervous system and blood diseases .

HY-P3683

*a-Helical Corticotropin Releasing* Factor (12-41)**	CRFR	Endocrinology
a-Helical Corticotropin Releasing Factor (12-41) is a 30 amino acids long, α-helical analogue of corticotropin releasing factor/hormone. Corticotropin releasing factor (CRF) is a hypothalamic hormone, which stimulates the secretion of adrenocorticotrophic hormone (ACTH). a-Helical Corticotropin Releasing Factor (12-41) would suppress the stimulatory effect .

HY-P3169

*a-Helical Corticotropin Releasing* Factor (9-41)**	CRFR	Inflammation/Immunology
α-Helical Corticotropin Releasing Factor (9-41) is a corticotropin releasing factor (CRF) antagonist. α-Helical Corticotropin Releasing Factor (9-41) decreases plasma growth hormone (GH) values in vivo .

HY-P3019A

Urocortin III (human) TFA	CRFR	Cardiovascular Disease Neurological Disease Metabolic Disease
Urocortin III (human) TFA is a corticotropin-releasing factor (CRF)-related peptide. Urocortin III (human) TFA preferentially binds and activates CRF-R2 and has a discrete central nervous system and peripheral distribution. Urocortin III (human) TFA potently binds to type 2 CRF receptors, specifically mCRF_2β (K_i = 13.5 nM) and rCRF_2α (K_i = 21.7 nM), while demonstrating negligible affinity for hCRF1 (K_i >100 nM). Urocortin III (human) TFA mediates somatostatin-dependent negative feedback control of Insulin (human) (HY-P0035) secretion .

HY-P3684A

*[DPro5] Corticotropin Releasing* Factor, human, rat TFA**	CRFR	Neurological Disease
[DPro5] Corticotropin Releasing Factor, human, rat TFA is a selective corticotropin releasing factor/hormone R2 (CRH-R2)agonist. [DPro5] Corticotropin Releasing Factor, human, rat TFA fails to cause the typical anxiogenic effect, but modulates learning and memory processes in rat .

HY-P1533A

CRF, bovine TFA 2 Publications Verification corticotropin releasing factor bovine TFA	CRFR	Inflammation/Immunology Endocrinology
CRF, bovine (TFA) is a potent agonist of CRF receptor, and displaces [ ¹²⁵I-Tyr]ovine CRF with a K_i of 3.52 nM .

HY-113603S

Tildacerfont-d8 SPR001-d₈; LY2371712-d₈	Isotope-Labeled Compounds CRFR	Cancer
Tildacerfont-d₈ (SPR001-d₈; LY2371712-d₈) is a deuterium labeled Tildacerfont (HY-113603). Tildacerfont (SPR001; LY2371712) is an orally active, blood-brain barrier-penetrant selective corticotropin-releasing factor type 1 (CRF1) receptor antagonist. Tildacerfont selectively blocks CRF1 receptors, thereby inhibiting the release of pituitary adrenocorticotropic hormone (ACTH). Tildacerfont can be used in research related to congenital adrenal hyperplasia .

HY-12130

CP 154526	CRFR	Neurological Disease
CP 154526 is a potent, brain-penetrant and selective corticotropin-releasing factor receptor 1 (CRF1) antagonist with a K_i of 2.7 nM. CP 154526 shows selective for CRF1 over CRF2 (K_i = >10 μM). CP 154526 has anxiolytic activities .

HY-12125

BMS-561388 benzenesulfonate	CRFR	Neurological Disease
BMS-561388 benzenesulfonate is a corticotropin-releasing factor receptor (CRFR) antagonist. BMS-561388 benzenesulfonate can be used for the research of neurological disease, such as anxiety and depression .

HY-103378

NBI 35965 methanesulfonate	CRFR	Neurological Disease
NBI 35965 methanesulfonate is a selective, orally active and brain-penetrant corticotropin-releasing factor receptor 1 (CRF1) antagonist with a K_i value of 4 nM and a pK_i value of 8.5. NBI 35965 methanesulfonate does not inhibit CRF2. NBI 35965 methanesulfonate reduces CRF or stress-induced adrenocorticotropic hormone (ACTH) production in vivo with pIC₅₀ values of 7.1 and 6.9, respectively. NBI 35965 methanesulfonate shows anxiolytic effects .

HY-169914

Igmesine hydrochloride JO 1784 hydrochloride	Sigma Receptor	Neurological Disease
Igmesine hydrochloride (JO 1784) is an orally active σ-receptor ligand capable of blocking the increase in colonic electromechanical activity induced by emotional stress. Igmesine hydrochloride also eliminates the colonic motility stimulation induced by dopamine, as well as the stimulation induced by centrally injected D1 or D2 receptor agonists. Furthermore, Igmesine hydrochloride can block the colonic motility responses induced by corticotropin-releasing factor (CRF) and ES through central cholecystokinin (CCK) release and/or activation of supraspinal CCK pathways .

HY-12132

DMP 904	CRFR Adenylate Cyclase	Neurological Disease
DMP 904 is a noncompetitive full corticotropin-releasing factor receptor (CRFR) antagonist. DMP 904 can inhibit CRF-stimulated adenylate cyclase activity and ACTH release. DMP 904 exhibits anti-depressant and anti-anxiety activity .

HY-P3685

*[Met(O)21] Corticotropin Releasing* Factor, ovine**	CRFR	Endocrinology
[Met(O)21] Corticotropin Releasing Factor, ovine is a corticotropin releasing factor isolated from ovine hypothalamic extracts. Corticotropin releasing factor (CRF) is a hypothalamic hormone, which stimulates the secretion of adrenocorticotrophic hormone (ACTH) .

HY-P3684

*[DPro5] Corticotropin Releasing* Factor, human, rat**	CRFR	Endocrinology
[DPro5] Corticotropin Releasing Factor, human, rat is a selective R2 agonist of corticotropin releasing factor/hormone. Corticotropin releasing factor (CRF) is a hypothalamic hormone, stimulates the release of adrenocorticotropic hormone (ACTH) and of β-endorphin. [DPro5] Corticotropin Releasing Factor, human, rat fails to cause the typical anxiogenic effect, but modulates learning and memory processes in rat .

HY-103376

NBI-27914 hydrochloride	CRFR	Neurological Disease
NBI-27914 (hydrochloride) is a selective Corticotropin-Releasing Factor 1 (CRF1) receptor antagonist with a K_i value of 1.7 nM .

HY-177313

AAG561 NVP-AAG 561	CFTR	Neurological Disease
AAG561 is a corticotropin-releasing factor receptor 1 (CRF1) antagonist. AAG561 can be used for the study of the underlying emotion dysregulation of a mental disease or disorder .

HY-P1533

CRF, bovine corticotropin releasing factor bovine	CRFR	Inflammation/Immunology Endocrinology
CRF, bovine is a potent agonist of CRF receptor, and displaces [ ¹²⁵I-Tyr]ovine CRF with a K_i of 3.52 nM.

HY-119114

E-2508 free base	CRFR	Neurological Disease
E-2508 free base is an orally active and highly selective corticotropin-releasing factor type 1 receptor (CRF1) antagonist with anxiolytic effects (K_i=11 nM). E-2508 free base blocks CRF-induced cAMP accumulation via CRF1 receptor inhibition. E-2508 free base is promising for research of stress-related psychiatric disorders, such as anxiety and depression .

HY-103379

CP 376395 hydrochloride	CRFR	Neurological Disease Endocrinology
CP 376395 hydrochloride is a potent, selective, and brain-penetrable Corticotropin releasing factor 1 (CRF1) receptor antagonist .

HY-P4012

[Asu1,6-Arg8]Vasopressin	Vasopressin Receptor	Endocrinology
[Asu1,6-Arg8]Vasopressin is an vasopressin agonist which potentiates cyclic AMP accumulation and ACTH release induced by corticotropin-releasing factor (CRF) in rat anterior pituitary cells in culture .

HY-124475R

Antalarmin (Standard)	CRFR	Neurological Disease
Antalarmin (Standard) is the analytical standard of Antalarmin. This product is intended for research and analytical applications. Antalarmin is a selective nonpeptide corticotropin-releasing factor receptor 1 (CRHR1) antagonist with a Ki of 2.7 nM. Antalarmin can pass through the blood–brain barrier .

HY-B1811R

Vasopressin (Standard) Arginine vasopressin (Standard); Antidiuretic hormone (Standard)	Endogenous Metabolite Reference Standards	Neurological Disease
Vasopressin (Standard) is the analytical standard of Vasopressin. This product is intended for research and analytical applications. Vasopressin is a cyclic nonapeptide that is synthesized centrally in the hypothalamus. Vasopressin participates in the hypothalamic-pituitary-adrenal axis, and regulates pituitary corticotropin secretion by potentiating the stimulatory effects of corticotropin releasing factor. Vasopressin also can act as a neurotransmitter, exerting its action by binding to specific G protein-coupled receptors .

HY-12339

NVS-CRF38	CRFR	Endocrinology
NVS-CRF38 is a novel corticotropin-releasing factor receptor 1 (CRF1) antagonist with low water solubility.

HY-123677

E2508	CRFR	Neurological Disease
E2508 is an orally active corticotropin-releasing factor 1 (CRF1) receptor antagonist with a K_i value of 11 nM for hCRF1 .

HY-120148

SM19712 free acid	Endothelin-Converting Enzyme (ECE)	Others
SM19712 (free acid) is an endothelin-converting enzyme-1-related compound that affects corticotropin-releasing factor receptor 1 (CRF1).

Cat. No.	Product Name	Target	Research Area

HY-B1811

Vasopressin Maximum Cited Publications 6 Publications Verification Arginine vasopressin; Antidiuretic hormone	Endogenous Metabolite	Neurological Disease
Vasopressin is a cyclic nonapeptide that is synthesized centrally in the hypothalamus. Vasopressin participates in the hypothalamic-pituitary-adrenal axis, and regulates pituitary corticotropin secretion by potentiating the stimulatory effects of corticotropin releasing factor. Vasopressin also can act as a neurotransmitter, exerting its action by binding to specific G protein-coupled receptors .

HY-P0086

Corticotropin-releasing factor (human) 3 Publications Verification Human CRF; Human corticotropin-releasing factor	CRFR	Neurological Disease
Corticotropin-releasing factor human (Human CRF) stimulates the synthesis and secretion of adrenocorticotropin in the anterior pituitary.

HY-P2847

Urocortin II, mouse	CRFR	Metabolic Disease Endocrinology
Urocortin II, mouse is a potent and selective endogenous peptide agonist of *type-2 corticotropin-releasing* factor (CRF2) receptor with K_i** values of 0.66 nM and ﹥100 nM for CRFR2 and CRFR1, respectively. Urocortin II, mouse activates CRF2 receptors in a cAMP/PKA- and Ca ²⁺/CaMKII-dependent manner.Urocortin II, mouse is expressed in discrete areas of the central nervous system, and activates central neurons involved in the processing of visceral sensory information, and in modulating autonomic outflow .

HY-P1752

Urocortin II, human	CRFR Bacterial Parasite NF-κB ERK	Metabolic Disease
Urocortin II, human is a selective endogenous peptide agonist of *type-2 corticotropin-releasing* factor (CRF2) receptor. Urocortin II, human has an effect of promoting satiet and neuroprotective effect. Urocortin II, human also has bactericidal, antiparasitic and pro-inflammation activity. Urocortin II, human can activate NF-κB pathway and ERK1/2 MAP** kinase. Urocortin II, human can reduce pulmonary arterial hypertension and shows cardiac protection effect. Urocortin II, human can be used for the researches of infection, inflammation, metabolic, neurological and cardiovascular disease .

HY-P1852

TIP 39, Tuberoinfundibular Neuropeptide 1 Publications Verification	Adenylate Cyclase PTHR	Neurological Disease
TIP 39, Tuberoinfundibular Neuropeptide is an endogenous PTH2 receptor agonist and antihypertensive agent. TIP 39, Tuberoinfundibular Neuropeptide selectively activates the PTH2 receptor with no activity on the PTH1 receptor, stimulates cAMP production, activates adenylate cyclase, and elevates intracellular calcium levels via mobilization from intracellular stores. TIP 39, Tuberoinfundibular Neuropeptide is highly conserved in humans, mice, and rats. TIP 39, Tuberoinfundibular Neuropeptide is applicable to research related to nociception and inflammation-induced pain .

HY-P3538

Corticotropin-releasing factor (Sheep) CRH (Sheep)	Peptides	Neurological Disease
Corticotropin-releasing factor (CRH) (Sheep) is a brain-penetrant hypothalamic releasing factor and a peptide hormone with analgesic and arousal-inducing activity. Corticotropin-releasing factor (Sheep) mediates stress effects, including stress-induced analgesia. Corticotropin-releasing factor (Sheep) increases wakefulness, reduces slow wave sleep, alters EEG frequency content, stimulates ACTH and β-endorphin release, activates locomotor activity. Corticotropin-releasing factor (Sheep) can be used for the research of neurological disease .

HY-P0257

Astressin 3 Publications Verification	CRFR	Neurological Disease
Astressin is a potent corticotropin releasing factor (CRF) antagonist.

HY-P2287

Cortagine 3 Publications Verification	CRFR	Neurological Disease
Cortagine is a specific corticotropin-releasing factor receptor subtype 1 (CRF1) agonist with an EC₅₀ of 2.6 nM for rCRF1. Cortagine is an anxiolytic and antidepressive agent in the mouse model .

HY-P1858A

Urocortin III, mouse TFA	CRFR	Cardiovascular Disease Neurological Disease Endocrinology
Urocortin III, mouse TFA is a corticotropin-releasing factor (CRF)-related peptide. Urocortin III preferentially binds and activates CRF-R2 . Urocortin III (Ucn3) is a known component of the behavioral stress response system. Urocortin III and CRF-R2 in the medial amygdala regulate complex social dynamics .

HY-P1858

Urocortin III, mouse	CRFR	Cardiovascular Disease Neurological Disease Endocrinology
Urocortin III, mouse is a corticotropin-releasing factor (CRF)-related peptide. Urocortin III preferentially binds and activates CRF-R2 . Urocortin III (Ucn3) is a known component of the behavioral stress response system. Urocortin III and CRF-R2 in the medial amygdala regulate complex social dynamics .

HY-P1298A

Sauvagine TFA	CRFR	Cardiovascular Disease Neurological Disease
Sauvagine TFA is a corticotropin-releasing factor receptor (CRFR) agonist. Sauvagine TFA activates HM-CRF receptors to stimulate intracellular cAMP accumulation, activates PC-CRF receptors to trigger associated signaling pathways, and stimulates the hypothalamic-pituitary-adrenal axis. Sauvagine TFA can be used for research on central nervous system and blood diseases .

HY-P3019

Urocortin III (human)	CRFR	Cardiovascular Disease Neurological Disease Endocrinology
Urocortin III (human) is a corticotropin-releasing factor (CRF)-related peptide. Urocortin III (human) preferentially binds and activates CRF-R2 and has a discrete central nervous system and peripheral distribution. Urocortin III (human) potently binds to type 2 CRF receptors, specifically mCRF_2β (K_i = 13.5 nM) and rCRF_2α (K_i = 21.7 nM), while demonstrating negligible affinity for hCRF1 (K_i >100 nM). Urocortin III (human) mediates somatostatin-dependent negative feedback control of Insulin (human) (HY-P0035) secretion ^[1][2].

HY-P1752B

Urocortin II, human acetate	CRFR Bacterial Parasite NF-κB ERK	Metabolic Disease
Urocortin II, human acetate is a selective endogenous peptide agonist of *type-2 corticotropin-releasing* factor (CRF2) receptor. Urocortin II, human acetate has an effect of promoting satiet and neuroprotective effect. Urocortin II, human acetate also has bactericidal, antiparasitic and pro-inflammation activity. Urocortin II, human acetate can activate NF-κB pathway and ERK1/2 MAP** kinase. Urocortin II, human acetate can reduce pulmonary arterial hypertension and shows cardiac protection effect. Urocortin II, human acetate can be used for the researches of infection, inflammation, metabolic, neurological and cardiovascular disease .

HY-P3687

*[Tyr0] Corticotropin Releasing* Factor, ovine**	CRFR	Endocrinology
[Tyr0] Corticotropin Releasing Factor, ovine is a corticotropin releasing factor/hormone isolated from ovine. Corticotropin releasing factor (CRF) is a hypothalamic hormone, stimulates the release of adrenocorticotropic hormone (ACTH) and of β-endorphin .

HY-P1298

Sauvagine	CRFR	Cardiovascular Disease Neurological Disease
Sauvagine is a corticotropin-releasing factor receptor (CRFR) agonist. Sauvagine activates HM-CRF receptors to stimulate intracellular cAMP accumulation, activates PC-CRF receptors to trigger associated signaling pathways, and stimulates the hypothalamic-pituitary-adrenal axis. Sauvagine can be used for research on central nervous system and blood diseases .

HY-P3683

*a-Helical Corticotropin Releasing* Factor (12-41)**	CRFR	Endocrinology
a-Helical Corticotropin Releasing Factor (12-41) is a 30 amino acids long, α-helical analogue of corticotropin releasing factor/hormone. Corticotropin releasing factor (CRF) is a hypothalamic hormone, which stimulates the secretion of adrenocorticotrophic hormone (ACTH). a-Helical Corticotropin Releasing Factor (12-41) would suppress the stimulatory effect .

HY-P3169

*a-Helical Corticotropin Releasing* Factor (9-41)**	CRFR	Inflammation/Immunology
α-Helical Corticotropin Releasing Factor (9-41) is a corticotropin releasing factor (CRF) antagonist. α-Helical Corticotropin Releasing Factor (9-41) decreases plasma growth hormone (GH) values in vivo .

HY-P3019A

Urocortin III (human) TFA	CRFR	Cardiovascular Disease Neurological Disease Metabolic Disease
Urocortin III (human) TFA is a corticotropin-releasing factor (CRF)-related peptide. Urocortin III (human) TFA preferentially binds and activates CRF-R2 and has a discrete central nervous system and peripheral distribution. Urocortin III (human) TFA potently binds to type 2 CRF receptors, specifically mCRF_2β (K_i = 13.5 nM) and rCRF_2α (K_i = 21.7 nM), while demonstrating negligible affinity for hCRF1 (K_i >100 nM). Urocortin III (human) TFA mediates somatostatin-dependent negative feedback control of Insulin (human) (HY-P0035) secretion .

HY-P3684A

*[DPro5] Corticotropin Releasing* Factor, human, rat TFA**	CRFR	Neurological Disease
[DPro5] Corticotropin Releasing Factor, human, rat TFA is a selective corticotropin releasing factor/hormone R2 (CRH-R2)agonist. [DPro5] Corticotropin Releasing Factor, human, rat TFA fails to cause the typical anxiogenic effect, but modulates learning and memory processes in rat .

HY-P1533A

CRF, bovine TFA 2 Publications Verification corticotropin releasing factor bovine TFA	CRFR	Inflammation/Immunology Endocrinology
CRF, bovine (TFA) is a potent agonist of CRF receptor, and displaces [ ¹²⁵I-Tyr]ovine CRF with a K_i of 3.52 nM .

HY-P3685

*[Met(O)21] Corticotropin Releasing* Factor, ovine**	CRFR	Endocrinology
[Met(O)21] Corticotropin Releasing Factor, ovine is a corticotropin releasing factor isolated from ovine hypothalamic extracts. Corticotropin releasing factor (CRF) is a hypothalamic hormone, which stimulates the secretion of adrenocorticotrophic hormone (ACTH) .

HY-P3684

*[DPro5] Corticotropin Releasing* Factor, human, rat**	CRFR	Endocrinology
[DPro5] Corticotropin Releasing Factor, human, rat is a selective R2 agonist of corticotropin releasing factor/hormone. Corticotropin releasing factor (CRF) is a hypothalamic hormone, stimulates the release of adrenocorticotropic hormone (ACTH) and of β-endorphin. [DPro5] Corticotropin Releasing Factor, human, rat fails to cause the typical anxiogenic effect, but modulates learning and memory processes in rat .

HY-P1533

CRF, bovine corticotropin releasing factor bovine	CRFR	Inflammation/Immunology Endocrinology
CRF, bovine is a potent agonist of CRF receptor, and displaces [ ¹²⁵I-Tyr]ovine CRF with a K_i of 3.52 nM.

HY-P4012

[Asu1,6-Arg8]Vasopressin	Vasopressin Receptor	Endocrinology
[Asu1,6-Arg8]Vasopressin is an vasopressin agonist which potentiates cyclic AMP accumulation and ACTH release induced by corticotropin-releasing factor (CRF) in rat anterior pituitary cells in culture .

HY-B1811R

Vasopressin (Standard) Arginine vasopressin (Standard); Antidiuretic hormone (Standard)	Endogenous Metabolite Reference Standards	Neurological Disease
Vasopressin (Standard) is the analytical standard of Vasopressin. This product is intended for research and analytical applications. Vasopressin is a cyclic nonapeptide that is synthesized centrally in the hypothalamus. Vasopressin participates in the hypothalamic-pituitary-adrenal axis, and regulates pituitary corticotropin secretion by potentiating the stimulatory effects of corticotropin releasing factor. Vasopressin also can act as a neurotransmitter, exerting its action by binding to specific G protein-coupled receptors .

HY-P3959

(Tyr0)-Urocortin, rat	CRFR	Endocrinology
(Tyr0)-Urocortin, rat is a high-affinity agonist of corticotropin-releasing factor receptor type 1 (CRF-R1) and type 2 (CRF-R2). (Tyr0)-Urocortin, rat shows inhibitory binding constants (Ki) of 1-2 nM .

HY-P1752A

Urocortin II, human TFA	CRFR Bacterial Parasite NF-κB ERK	Metabolic Disease
Urocortin II, human TFA is a selective endogenous peptide agonist of *type-2 corticotropin-releasing* factor (CRF2) receptor. Urocortin II, human TFA has an effect of promoting satiet and neuroprotective effect. Urocortin II, human TFA also has bactericidal, antiparasitic and pro-inflammation activity. Urocortin II, human TFA can activate NF-κB pathway and ERK1/2 MAP** kinase. Urocortin II, human TFA can reduce pulmonary arterial hypertension and shows cardiac protection effect. Urocortin II, human TFA can be used for the researches of infection, inflammation, metabolic, neurological and cardiovascular disease .

HY-P11461

Biotin-CRF, human, rat Biotin-corticotropin releasing factor	Drug Derivative	Neurological Disease
Biotin-CRF, human, rat is a biotin-conjugated CRF (human, rat). CRF (human, rat) is a corticotropin-releasing hormone, paraventricular hypothalamic nucleus marker .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-B1811

Vasopressin Maximum Cited Publications 6 Publications Verification Arginine vasopressin; Antidiuretic hormone	Structural Classification Neurological Disease Classification of Application Fields Cyclopeptides Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite
Vasopressin is a cyclic nonapeptide that is synthesized centrally in the hypothalamus. Vasopressin participates in the hypothalamic-pituitary-adrenal axis, and regulates pituitary corticotropin secretion by potentiating the stimulatory effects of corticotropin releasing factor. Vasopressin also can act as a neurotransmitter, exerting its action by binding to specific G protein-coupled receptors .

HY-B1811R

Vasopressin (Standard) Arginine vasopressin (Standard); Antidiuretic hormone (Standard)	Structural Classification Cyclopeptides Endogenous metabolite Source Classification	Endogenous Metabolite Reference Standards
Vasopressin (Standard) is the analytical standard of Vasopressin. This product is intended for research and analytical applications. Vasopressin is a cyclic nonapeptide that is synthesized centrally in the hypothalamus. Vasopressin participates in the hypothalamic-pituitary-adrenal axis, and regulates pituitary corticotropin secretion by potentiating the stimulatory effects of corticotropin releasing factor. Vasopressin also can act as a neurotransmitter, exerting its action by binding to specific G protein-coupled receptors .

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P70013

	CRHBP Protein, Human (HEK293, His) rHucorticotropin-releasing factor-binding protein/CRHBP, His ; corticotropin-releasing factor-Binding Protein; CRF-BP; CRF-Binding Protein; corticotropin-releasing Hormone-Binding Protein; CRH-BP; CRHBP; CRFBP	Human	HEK293
	CRHBP Protein critically regulates by binding to and inactivating corticotropin-releasing factor (CRF), suggesting a role in preventing excessive pituitary-adrenal stimulation, especially during pregnancy. This interaction contributes to balancing neuroendocrine signaling pathways, ensuring appropriate physiological responses and safeguarding against pituitary-adrenal axis overstimulation, particularly in the context of pregnancy. CRHBP Protein, Human (HEK293, His) is the recombinant human-derived CRHBP protein, expressed by HEK293 , with C-6*His labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-B1811AS1

Vasopressin-d5 TFA

Vasopressin-d5 TFA is the TFA salt form of Vasopressin-d5 (HY-B1811S1). Vasopressin-d5 TFA is an isotope-labeled compound of Vasopressin (HY-B1811). Vasopressin is a cyclic nonapeptide that is synthesized centrally in the hypothalamus. Vasopressin participates in the hypothalamic-pituitary-adrenal axis and regulates pituitary corticotropin secretion by potentiating the stimulatory effects of the corticotropin-releasing factor. Vasopressin also can act as a neurotransmitter, exerting its action by binding to specific G protein-coupled receptors .

HY-113603S

Tildacerfont-d8

Tildacerfont-d₈ (SPR001-d₈; LY2371712-d₈) is a deuterium labeled Tildacerfont (HY-113603). Tildacerfont (SPR001; LY2371712) is an orally active, blood-brain barrier-penetrant selective corticotropin-releasing factor type 1 (CRF1) receptor antagonist. Tildacerfont selectively blocks CRF1 receptors, thereby inhibiting the release of pituitary adrenocorticotropic hormone (ACTH). Tildacerfont can be used in research related to congenital adrenal hyperplasia .

HY-B1811S1

Vasopressin-d5

Vasopressin-d5 is anIsotope-labeled compound of Vasopressin. Vasopressin is a cyclic nonapeptide that is synthesized centrally in the hypothalamus. Vasopressin participates in the hypothalamic-pituitary-adrenal axis and regulates pituitary corticotropin secretion by potentiating the stimulatory effects of the corticotropin-releasing factor. Vasopressin also can act as a neurotransmitter, exerting its action by binding to specific G protein-coupled receptors .

Cat. No.	Product Name		Classification

HY-106203

Crinecerfont SSR-125543		Alkynes
Crinecerfont (SSR-125543) is an orally effective corticotropin-releasing factor receptor type-1 (CRF1 receptor) antagonist. Crinecerfont blocks CRF1 receptor signaling to reduce adrenocorticotropic hormone secretion. Crinecerfont improves hypothalamic-pituitary-adrenal axis negative feedback sensitivity in chronically stressed mice. Crinecerfont can be used for the research of chronic stress conditions and classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency . Crinecerfont is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-106203A

Crinecerfont hydrochloride SSR-125543 hydrochloride		Alkynes
Crinecerfont (SSR-125543) hydrochloride is an orally effective corticotropin-releasing factor receptor type-1 (CRF1 receptor) antagonist. Crinecerfont hydrochloride blocks CRF1 receptor signaling to reduce adrenocorticotropic hormone secretion. Crinecerfont hydrochloride improves hypothalamic-pituitary-adrenal axis negative feedback sensitivity in chronically stressed mice. Crinecerfont hydrochloride can be used for the research of chronic stress conditions and classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency . Crinecerfont hydrochloride is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-106203B

(R)-Crinecerfont (R)-SSR-125543		Alkynes
(R)-Crinecerfont is the R-enantiomer of Crinecerfont (HY-106203). Crinecerfont (SSR-125543) is an orally effective corticotropin-releasing factor receptor type-1 (CRF1 receptor) antagonist. Crinecerfont blocks CRF1 receptor signaling to reduce adrenocorticotropic hormone secretion. Crinecerfont improves hypothalamic-pituitary-adrenal axis negative feedback sensitivity in chronically stressed mice. Crinecerfont can be used for the research of chronic stress conditions and classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency . Crinecerfont is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Cat. No.	Product Name		Classification

HY-174545

Human POU3F2 mRNA		mRNA Transcription Factors
Human POU3F2 mRNA encodes the human POU class 3 homeobox 2 (POU3F2) protein, a member of the POU-III class of neural transcription factors. POU3F2 is involved in neuronal differentiation and enhances the activation of corticotropin-releasing hormone regulated genes.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

corticotropin-releasing factor

Inhibitors & Agonists

Peptides

NaturalProducts

Recombinant Proteins

Isotope-Labeled Compounds

Click Chemistry

Oligonucleotides

Natural
Products